Skip to main content
SpringerLink
Log in

Contemporary Approaches for Malaria Drug Discovery

  • Chapter
  • First Online:
Drug Design: Principles and Applications

  • 1328 Accesses

Abstract

Malaria is a major global health problem, caused by Plasmodium sps. Clinical symptoms of the disease are associated with asexual stages of parasite life cycle in human erythrocytes whereas transmission of disease is attributed to sexual stages in mosquito. Increasing resistance to known antimalarial drugs has resulted in the evolution of newer approaches of drug discovery against the disease. The conventional phenotypic screening approaches of drug discovery enable high-throughput screening of a library of chemical compounds for antimalarial effect followed by target identification and its experimental validation. Alternatively, target-based approach for drug discovery involves screening of compounds against known parasite targets by in vitro and in vivo studies. This chapter focuses on the contemporary approaches in antimalarial drug discovery that promise the development of an effective strategy to combat malaria.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Health Organization (2015) World Malaria Report [online]. http://www.who.int/malaria/publications/world_malaria_report_2015/en/

  2. Roll Back Malaria Partnership (2008) Roll Back Malaria [online]. http://www.rollbackmalaria.org/microsites/gmap/GMAP_Advocacy-ENG-web.pdf

  3. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413–431. doi:10.1016/S0140-6736(12)60034-8

    Article  PubMed  Google Scholar 

  4. Baird JK, Schwartz E, Hoffman SL (2007) Prevention and treatment of vivax malaria. Curr Infect Dis Rep 9:39–46

    Article  PubMed  Google Scholar 

  5. Singh B, Daneshvar C (2013) Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 26:165–184. doi:10.1128/CMR.00079-12

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Ballou WR, Kester KE, Stoute JA, Heppner DG (1999) Malaria vaccines: triumphs or tribulations? Parassitologia 41:403–408

    CAS  PubMed  Google Scholar 

  7. Flannery EL, Chatterjee AK, Winzeler EA (2013) Antimalarial drug discovery—approaches and progress towards new medicines. Nat Rev Microbiol 11:849–862. doi:10.1038/nrmicro3138

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619–2620. doi:10.1056/NEJMc0805011

    Article  CAS  PubMed  Google Scholar 

  9. Mutabingwa TK (2005) Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop 95:305–315. doi:10.1016/j.actatropica.2005.06.009

    Article  CAS  PubMed  Google Scholar 

  10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467. doi:10.1056/NEJMoa0808859

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F (2012) Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379:1960–1966. doi:10.1016/S0140-6736(12)60484-X

    Article  PubMed Central  PubMed  Google Scholar 

  12. Mohon AN, Alam MS, Bayih AG, Folefoc A, Shahinas D, Haque R, Pillai DR (2014) Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013). Malar J 13:431. doi:10.1186/1475-2875-13-431

    Article  PubMed Central  PubMed  Google Scholar 

  13. Bayih AG, Getnet G, Alemu A, Getie S, Mohon AN, Pillai DR (2016) A unique Plasmodium falciparum K13 gene mutation in Northwest Ethiopia. Am J Trop Med Hyg 94:132–135. doi:10.4269/ajtmh.15-0477

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Tanner M, de Savigny D (2008) Malaria eradication back on the table. Bull World Health Organ 86:82

    Article  PubMed Central  PubMed  Google Scholar 

  15. Kappe SH, Vaughan AM, Boddey JA, Cowman AF (2010) That was then but this is now: malaria research in the time of an eradication agenda. Science 328:862–866. doi:10.1126/science.1184785

    Article  CAS  PubMed  Google Scholar 

  16. Lengeler C (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2(2):CD000363. doi:10.1002/14651858.CD000363.pub2

    Google Scholar 

  17. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, Moonen B (2012) Malaria resurgence: a systematic review and assessment of its causes. Malar J 11:122. doi:10.1186/1475-2875-11-122

    Article  PubMed Central  PubMed  Google Scholar 

  18. Roll Back Malaria Partnership (2008) The global malaria action plan for a malaria-free world. Roll Back Malaria [online]. http://archiverbm.rollbackmalaria.org/gmap/gmap.pdf

  19. Munter S, Way M, Frischknecht F (2006) Signaling during pathogen infection. Sci STKE 2006:re5. doi:10.1126/stke.3352006re5

    PubMed  Google Scholar 

  20. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M (2011) A research agenda to underpin malaria eradication. PLoS Med 8:e1000406. doi:10.1371/journal.pmed.1000406

    Article  PubMed Central  PubMed  Google Scholar 

  21. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN (2013) Designing the next generation of medicines for malaria control and eradication. Malar J 12:187. doi:10.1186/1475-2875-12-187

    Article  PubMed Central  PubMed  Google Scholar 

  22. Rao VB, Schellenberg D, Ghani AC (2013) Overcoming health systems barriers to successful malaria treatment. Trends Parasitol 29:164–180. doi:10.1016/j.pt.2013.01.005

    Article  PubMed  Google Scholar 

  23. Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy AW, Bjorkman A, Kallander K (2009) Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Int Health 14:766–774. doi:10.1111/j.1365-3156.2009.02289.x

    Article  CAS  PubMed  Google Scholar 

  24. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF, Marti M (2011) A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J Infect Dis 203:1445–1453. doi:10.1093/infdis/jir037

    Article  PubMed Central  PubMed  Google Scholar 

  25. Derbyshire ER, Mota MM, Clardy J (2011) The next opportunity in anti-malaria drug discovery: the liver stage. PLoS Pathog 7:e1002178. doi:10.1371/journal.ppat.1002178

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrian F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA (2008) In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A 105:9059–9064. doi:10.1073/pnas.0802982105

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465:305–310. doi:10.1038/nature09107

    Article  CAS  PubMed  Google Scholar 

  28. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DV, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10:188–195. doi:10.1038/nrd3368

    Article  CAS  PubMed  Google Scholar 

  29. Lucantoni L, Avery V (2012) Whole-cell in vitro screening for gametocytocidal compounds. Future Med Chem 4:2337–2360. doi:10.4155/fmc.12.188

    Article  CAS  PubMed  Google Scholar 

  30. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507–519. doi:10.1038/nrd3480

    Article  CAS  PubMed  Google Scholar 

  31. Peatey CL, Spicer TP, Hodder PS, Trenholme KR, Gardiner DL (2011) A high-throughput assay for the identification of drugs against late-stage Plasmodium falciparum gametocytes. Mol Biochem Parasitol 180:127–131. doi:10.1016/j.molbiopara.2011.09.002

    Article  CAS  PubMed  Google Scholar 

  32. Limenitakis J, Soldati-Favre D (2011) Functional genetics in Apicomplexa: potentials and limits. FEBS Lett 585:1579–1588. doi:10.1016/j.febslet.2011.05.002

    Article  CAS  PubMed  Google Scholar 

  33. Lacroix C, Giovannini D, Combe A, Bargieri DY, Spath S, Panchal D, Tawk L, Thiberge S, Carvalho TG, Barale JC, Bhanot P, Menard R (2011) FLP/FRT-mediated conditional mutagenesis in pre-erythrocytic stages of Plasmodium berghei. Nat Protoc 6:1412–1428. doi:10.1038/nprot.2011.363

    Article  CAS  PubMed  Google Scholar 

  34. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT (2010) Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175–1180. doi:10.1126/science.1193225

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH (2010) Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem 53:5155–5164. doi:10.1021/jm100410f

    Article  CAS  PubMed  Google Scholar 

  36. Krishna S, Woodrow C, Webb R, Penny J, Takeyasu K, Kimura M, East JM (2001) Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem 276:10782–10787. doi:10.1074/jbc.M010554200

    Article  CAS  PubMed  Google Scholar 

  37. White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, Jeeyapant A, Jain JP, Lefevre G, Li R, Magnusson B, Diagana TT, Leong FJ (2014) Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med 371:403–410. doi:10.1056/NEJMoa1315860

    Article  PubMed Central  PubMed  Google Scholar 

  38. Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K (2013) Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13:227–237. doi:10.1016/j.chom.2012.12.006

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Leong FJ, Zhao R, Zeng S, Magnusson B, Diagana TT, Pertel P (2014) A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother 58:6437–6443. doi:10.1128/AAC.03478-14

    Article  PubMed Central  PubMed  Google Scholar 

  40. Younis Y, Douelle F, Feng TS, Gonzalez Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery V, Charman SA, Chibale K (2012) 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem 55:3479–3487. doi:10.1021/jm3001373

    Article  CAS  PubMed  Google Scholar 

  41. McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Dechering KJ, Kumar TR, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA (2013) Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504:248–253. doi:10.1038/nature12782

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Calderon F, Barros D, Bueno JM, Coteron JM, Fernandez E, Gamo FJ, Lavandera JL, Leon ML, Macdonald SJ, Mallo A, Manzano P, Porras E, Fiandor JM, Castro J (2011) An invitation to open innovation in malaria drug discovery: 47 quality starting points from the TCAMS. ACS Med Chem Lett 2:741–746. doi:10.1021/ml200135p

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Calderon F, Vidal-Mas J, Burrows J, de la Rosa JC, Jimenez-Diaz MB, Mulet T, Prats S, Solana J, Witty M, Gamo FJ, Fernandez E (2012) A divergent SAR study allows optimization of a potent 5-HT2c inhibitor to a promising antimalarial scaffold. ACS Med Chem Lett 3:373–377. doi:10.1021/ml300008j

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Rueda L, Castellote I, Castro-Pichel J, Chaparro MJ, de la Rosa JC, Garcia-Perez A, Gordo M, Jimenez-Diaz MB, Kessler A, Macdonald SJ, Martinez MS, Sanz LM, Gamo FJ, Fernandez E (2011) Cyclopropyl carboxamides: a new oral antimalarial series derived from the Tres Cantos Anti-Malarial Set (TCAMS). ACS Med Chem Lett 2:840–844. doi:10.1021/ml2001517

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Sanz LM, Jimenez-Diaz MB, Crespo B, De-Cozar C, Almela MJ, Angulo-Barturen I, Castaneda P, Ibanez J, Fernandez EP, Ferrer S, Herreros E, Lozano S, Martinez MS, Rueda L, Burrows JN, Garcia-Bustos JF, Gamo FJ (2011) Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob Agents Chemother 55:5740–5745. doi:10.1128/AAC.05188-11

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK (2012) Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem 55:4244–4273. doi:10.1021/jm300041e

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Wu T, Nagle A, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Goh A, Lakshminarayana SB, Wu J, Ang HQ, Zeng P, Kang ML, Tan W, Tan M, Ye N, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Hollenbeck T, Tuntland T, Isbell J, Fischli C, Brun R, Rottmann M, Dartois V, Keller T, Diagana T, Winzeler E, Glynne R, Tully DC, Chatterjee AK (2011) Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J Med Chem 54:5116–5130. doi:10.1021/jm2003359

    Article  CAS  PubMed  Google Scholar 

  48. Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT (2014) KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother 58:5060–5067. doi:10.1128/AAC.02727-13

    Article  PubMed Central  PubMed  Google Scholar 

  49. Anthony MP, Burrows JN, Duparc S, Moehrle JJ, Wells TN (2012) The global pipeline of new medicines for the control and elimination of malaria. Malar J 11:316. doi:10.1186/1475-2875-11-316

    Article  PubMed Central  PubMed  Google Scholar 

  50. Dong Y, Wittlin S, Sriraghavan K, Chollet J, Charman SA, Charman WN, Scheurer C, Urwyler H, Santo Tomas J, Snyder C, Creek DJ, Morizzi J, Koltun M, Matile H, Wang X, Padmanilayam M, Tang Y, Dorn A, Brun R, Vennerstrom JL (2010) The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). J Med Chem 53:481–491. doi:10.1021/jm901473s

    Article  CAS  PubMed  Google Scholar 

  51. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN (2004) Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900–904. doi:10.1038/nature02779

    Article  CAS  PubMed  Google Scholar 

  52. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, Tilley L (2011) Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A 108:11405–11410. doi:10.1073/pnas.1104063108

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Olliaro P, Wells TN (2009) The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 85:584–595. doi:10.1038/clpt.2009.51

    Article  CAS  PubMed  Google Scholar 

  54. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL (2011) Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 108:4400–4405. doi:10.1073/pnas.1015762108

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. O’Neill PM, Amewu RK, Nixon GL, Bousejra ElGarah F, Mungthin M, Chadwick J, Shone AE, Vivas L, Lander H, Barton V, Muangnoicharoen S, Bray PG, Davies J, Park BK, Wittlin S, Brun R, Preschel M, Zhang K, Ward SA (2010) Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew Chem Int Ed Engl 49:5693–5697. doi:10.1002/anie.201001026

    Article  PubMed  Google Scholar 

  56. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993–996. doi:10.1038/nrd2199

    Article  CAS  PubMed  Google Scholar 

  57. Mullard A (2013) European lead factory opens for business. Nat Rev Drug Discov 12:173–175. doi:10.1038/nrd3956

    Article  PubMed  Google Scholar 

  58. O’Neill PM, Ward SA, Berry NG, Jeyadevan JP, Biagini GA, Asadollaly E, Park BK, Bray PG (2006) A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem 6:479–507

    Article  PubMed  Google Scholar 

  59. Doerig C, Meijer L (2007) Antimalarial drug discovery: targeting protein kinases. Expert Opin Ther Targets 11:279–290. doi:10.1517/14728222.11.3.279

    Article  PubMed  Google Scholar 

  60. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K (2009) Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science 325:1680–1682. doi:10.1126/science.1175667

    Article  CAS  PubMed  Google Scholar 

  61. Seeber F, Soldati-Favre D (2010) Metabolic pathways in the apicoplast of apicomplexa. Int Rev Cell Mol Biol 281:161–228. doi:10.1016/S1937-6448(10)81005-6

    Article  CAS  PubMed  Google Scholar 

  62. Grellier P, Depoix D, Schrevel J, Florent I (2008) Discovery of new targets for antimalarial chemotherapy. Parasite 15:219–225. doi:10.1051/parasite/2008153219

    Article  CAS  PubMed  Google Scholar 

  63. Dong CK, Urgaonkar S, Cortese JF, Gamo FJ, Garcia-Bustos JF, Lafuente MJ, Patel V, Ross L, Coleman BI, Derbyshire ER, Clish CB, Serrano AE, Cromwell M, Barker RH Jr, Dvorin JD, Duraisingh MT, Wirth DF, Clardy J, Mazitschek R (2011) Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem Biol 18:1602–1610. doi:10.1016/j.chembiol.2011.09.016

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Nam TG, McNamara CW, Bopp S, Dharia NV, Meister S, Bonamy GM, Plouffe DM, Kato N, McCormack S, Bursulaya B, Ke H, Vaidya AB, Schultz PG, Winzeler EA (2011) A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol 6:1214–1222. doi:10.1021/cb200105d

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O’Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK (2014) (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A 111:E5455–E5462. doi:10.1073/pnas.1414221111

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  66. Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A 109:16823–16828. doi:10.1073/pnas.1204556109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Turbachova I, Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E (1999) Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285:1573–1576

    Article  CAS  PubMed  Google Scholar 

  68. Deng X, Kokkonda S, El Mazouni F, White J, Burrows JN, Kaminsky W, Charman SA, Matthews D, Rathod PK, Phillips MA (2014) Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J Med Chem 57:5381–5394. doi:10.1021/jm500481t

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodrigues T, Sonnichsen B, Moreira R, Gamo FJ, Marti M, Mota MM, Hannus M, Prudencio M (2012) Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis 205:1278–1286. doi:10.1093/infdis/jis184

    Article  PubMed Central  PubMed  Google Scholar 

  70. Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R, Aust T, McCormack SL, Plouffe DM, Meister S, Schuierer S, Plikat U, Hartmann N, Staedtler F, Cotesta S, Schmitt EK, Petersen F, Supek F, Glynne RJ, Tallarico JA, Porter JA, Fishman MC, Bodenreider C, Diagana TT, Movva NR, Winzeler EA (2012) Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 11:654–663. doi:10.1016/j.chom.2012.04.015

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Hsu E (2006) Reflections on the ‘discovery’ of the antimalarial qinghao. Br J Clin Pharmacol 61:666–670. doi:10.1111/j.1365-2125.2006.02673.x

    Article  PubMed Central  PubMed  Google Scholar 

  72. Willcox M, Falquet J, Ferreira JF, Gilbert B, Hsu E, de Magalhaes PM, Plaizier-Vercammen J, Sharma VP, Wright CW, Yaode W (2006) Artemisia annua as a herbal tea for malaria. Afr J Tradit Complement Altern Med 4:121–123

    PubMed  Google Scholar 

  73. Wells TN (2011) Natural products as starting points for future anti-malarial therapies: going back to our roots? Malar J 10(Suppl 1):S3. doi:10.1186/1475-2875-10-S1-S3

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Willcox ML, Graz B, Falquet J, Diakite C, Giani S, Diallo D (2011) A “reverse pharmacology” approach for developing an anti-malarial phytomedicine. Malar J 10(Suppl 1):S8. doi:10.1186/1475-2875-10-S1-S8

    Article  PubMed Central  PubMed  Google Scholar 

  75. Mesia K, Cimanga RK, Dhooghe L, Cos P, Apers S, Totte J, Tona GL, Pieters L, Vlietinck AJ, Maes L (2010) Antimalarial activity and toxicity evaluation of a quantified Nauclea pobeguinii extract. J Ethnopharmacol 131:10–16. doi:10.1016/j.jep.2010.05.008

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Life Sciences, Shiv Nadar University, Gautam Buddha Nagar, Dadri, UP, 201314, India

    Vijeta Sharma & Shailja Singh

  2. Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067, India

    Sonal Gupta & Shailja Singh

Authors
  1. Vijeta Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonal Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shailja Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shailja Singh .

Editor information

Editors and Affiliations

  1. School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

    Abhinav Grover

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Sharma, V., Gupta, S., Singh, S. (2017). Contemporary Approaches for Malaria Drug Discovery. In: Grover, A. (eds) Drug Design: Principles and Applications. Springer, Singapore. https://doi.org/10.1007/978-981-10-5187-6_4

Download citation

Publish with us

Policies and ethics

Search

Navigation